The recall comes years after surgeons say they first noticed problems with the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories. The devices are not currently being removed from the market.
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Food and Drug Administration gave an emergency use authorization to two more over-the-counter Covid-19 tests that can be used without a prescription. They include Abbott’s BinaxNow test and an at-home test developed by Quidel Corp.
Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories particularly, the risk of infection to those handling it.
Abbott touted its Absorb fully-resorbable coronary scaffold but physicians never saw clear clinical benefit over the standard of treatment leading the company to halt sales of the expensive device just over a year after FDA approval.
Despite the week ending on a high note for Abbott Laboratories with an amended $5.3 billion deal to buy Alere, a warning letter from the U.S. Food and Drug Administration drew attention to issues at another Abbott acquisition — St. Jude Medical.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Abbott wants out of its plan to buy Alere for $5.8 billion, but the point-of-care testing company is a perfect fit for Abbott, an analyst believes.
Abbott Labs filed a complaint in a Delaware court citing that Alere has numerous problems and the court should allow it to bow out of its proposed plan to buy Alere for $5.8 billion.
A doctor argues that bioresorbable stents value is questionable now despite the marketing and the hype.
Abbott Laboratories is paying $225M for the heart valve replacement developer Tendyne, and NuVasive is spending $13.5M in order to settle after false Medicare claim allegations.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
TOP STORIES The federal government detailed drug spending, detailing doctor-by-doctor and drug-by-drug how Medicare and its beneficiaries spent $103 billion on pharmaceuticals in 2013. Isis Pharmaceuticals, Inc. announced it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. LIFE SCIENCE Italian biotech […]
Abbott Labs (ABT) announced it received FDA approval for MitraClip, a less-invasive mitral valve repair technology. The device allows physicians to repair the mitral valve using a catheter rather than open heart surgery for patients with mitral regurgitation. The company will launch the product in the U.S. immediately. While open heart mitral valve surgery is […]
In this week’s healthcare design reading roundup, there’s innovation in medical device design, a hard look at the actual materials that make wearable tech wearable and a thoughtful discussion of how healing art should operate in labor and delivery. 1. Abbott is designing a stent that dissolves inside the body. 2. The five materials making […]
(Reuters) - A slim majority of advisers to the U.S. Food and Drug Administration voted on Wednesday for approval of Abbott Laboratories' implantable heart device MitraClip, saying it had more benefits than risks. The eight members of the advisory panel...
Abbott Laboratories (NYSE:ABT) is planning a $270 million plant in Southwest Ohio that will make adult liquid nutrition products Ensure and Glucerna. The plant in Tipp City, Ohio is expected to be operational by late next year, with groundbreaking to come this April, according to a statement from Chicago-area Abbott. The plant is expected to […]